EichorEICHOR
Location: Maumee Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Maumee

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Taylor Cancer Research Center ( Site 9500) · Merck Sharp & Dohme LLC · NCT06393374A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Phase N/A · Taylor Cancer Research Center · Tempus AI · NCT07154823A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 · Taylor Cancer Research Center · Fore Biotherapeutics · NCT05503797A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · Taylor Cancer Research Center · Artios Pharma Ltd · NCT04657068VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/Phase 2 · Taylor Cancer Research Center (site 204) · VM Oncology, LLC · NCT03556228Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC Wi
Phase 3 · Research Site · AstraZeneca · NCT06357533GEMINI-NSCLC: NSCLC Biomarker Study
Phase N/A · Taylor Cancer Research Center · Tempus AI · NCT05236114Pan-tumor MRD Study
Phase N/A · Taylor Cancer Research Center · Paradigm Health · NCT06605404Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/Phase 2 · Taylor Cancer Research Center · Revolution Medicines, Inc. · NCT05379985A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants Wi
Phase 3 · Research Site · AstraZeneca · NCT05211895Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 · Taylor Cancer Research Center · Revolution Medicines, Inc. · NCT06881784Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Toledo Clinic Cancer Centers-Maumee · ECOG-ACRIN Cancer Research Group · NCT04566328Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease o
Phase 3 · Clinical Trial Site · Alnylam Pharmaceuticals · NCT07181109A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Meta
Phase 2 · Taylor Cancer Research Center · Puma Biotechnology, Inc. · NCT06369285mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Toledo Clinic Cancer Centers-Maumee · Alliance for Clinical Trials in Oncology · NCT05677490A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Phase 1/Phase 2 · Taylor Cancer Research Center · Nimbus Wadjet, Inc. · NCT06898450TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Phase N/A · Taylor Cancer Research Center · Tempus AI · NCT06207032A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip
Phase 3 · Taylor Cancer Research Center · Bayer · NCT06452277Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · Taylor Cancer Research Center · Tasca Therapeutics · NCT07030257Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Toledo Clinic Cancer Centers-Maumee · SWOG Cancer Research Network · NCT04205968AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · Taylor Cancer Research Center · Carna Biosciences, Inc. · NCT05602363A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Phase 1/Phase 2 · Taylor Cancer Research Center · TRIANA Biomedicines, Inc. · NCT07491497A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 · Taylor Cancer Research Center · Astellas Pharma Inc · NCT05382559A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Phase 1/Phase 2 · Taylor Cancer Research Center · Pathos AI, Inc. · NCT06785636S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic
NA · Toledo Clinic Cancer Centers-Maumee · SWOG Cancer Research Network · NCT03723928Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Phase 3 · Research Site · AstraZeneca · NCT06307652Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcino
Phase 3 · Taylor Cancer Research Center · Revolution Medicines, Inc. · NCT07491445Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Phase 2 · Taylor Cancer Research Center · Boehringer Ingelheim · NCT06581432A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doub
Phase 3 · Research Site · AstraZeneca · NCT06417814Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Phase 2 · Advanced Medical Research · Regeneron Pharmaceuticals · NCT07175428
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.